BeOne Medicines (ONC) Capital Expenditures (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | BeOne Medicines | - | - | 1.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67.67% |
| Dec 31, 2025 | 2,380.63% |
| Sep 30, 2025 | -181.07% |
| Jun 30, 2025 | -103.48% |
| Mar 31, 2025 | 118.19% |
| Dec 31, 2024 | -346.81% |
| Sep 30, 2024 | 21.56% |
| Jun 30, 2024 | 273.59% |
| Mar 31, 2024 | -93.52% |
| Dec 31, 2023 | 425.78% |
| Sep 30, 2023 | -176.18% |
| Jun 30, 2023 | 185.95% |
| Mar 31, 2023 | -47.25% |
| Dec 31, 2022 | 11.69% |
| Sep 30, 2022 | 116.06% |
| Jun 30, 2022 | 11.43% |
| Mar 31, 2022 | 147.62% |
| Dec 31, 2021 | -241.35% |
| Sep 30, 2021 | 34.05% |
| Jun 30, 2021 | 61.83% |
| Mar 31, 2021 | -64.30% |
| Dec 31, 2020 | 4,308.45% |
| Sep 30, 2020 | -73.56% |
| Jun 30, 2020 | -65.50% |
| Mar 31, 2020 | -64.32% |
| Dec 31, 2019 | 1,004.63% |
| Sep 30, 2019 | -147.32% |
| Jun 30, 2019 | -35.41% |
| Mar 31, 2019 | 187.58% |
| Dec 31, 2018 | -163.87% |
| Sep 30, 2018 | 2,409.05% |
| Jun 30, 2018 | -117.43% |
| Mar 31, 2018 | 138.44% |
| Dec 31, 2017 | -235.92% |
| Sep 30, 2017 | 177.97% |
| Jun 30, 2017 | 202.95% |
| Mar 31, 2017 | -90.49% |
| Dec 31, 2016 | 374.71% |
| Sep 30, 2016 | -254.70% |
| Jun 30, 2016 | 65.15% |
| Mar 31, 2016 | 276.73% |
| Dec 31, 2015 | -200.70% |
| Sep 30, 2015 | 158.07% |
| Jun 30, 2015 | -198.89% |